Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning, everyone. Damian here with a special thanks to everyone who joined us for STAT’s live event in New York City last night. Today we have a sober look at the future of mRNA, a plot to bring CAR-T back to its founding ideals, and the downside of a billion-dollar buyout.
The need-to-know this morning
• Amicus Therapeutics Executive Chairman John Crowley is stepping down from the board to become CEO of the trade group BIO.
CRISPR Therapeutics is discontinuing the development of two, off-the-shelf CAR-T treatments for blood cancer, shifting to “next generation” versions of the products that have the potential to be more effective. The company also plans develop a CAR-T treatment for the autoimmune disease lupus.
• In a business review with investors and analysts, Johnson & Johnson provided financial guidance for 2024 and long-term operational sales outlook through 2030. STAT’s Matt Herper spoke to J&J’s new R&D chief John Reed about his drug-development strategy.
• BridgeBio completed the filing of a marketing application to the FDA for its heart disease drug acoramidis.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect